Nephrotoxic Risk Associated With Combination Therapy of Vancomycin and Piperacillin-Tazobactam in Critically Ill Patients With Chronic Kidney Disease

被引:0
|
作者
Pipkin, Tamyah [1 ,7 ]
Pope, Stuart [2 ,8 ]
Killian, Alley [1 ]
Green, Sarah [1 ]
Albrecht, Benjamin [1 ]
Nugent, Katherine [3 ,4 ,5 ,6 ]
机构
[1] Emory Univ Hosp, Dept Pharm, Atlanta, GA USA
[2] Emory Univ Hosp Midtown, Dept Pharm, Atlanta, GA USA
[3] Emory Univ, Dept Med, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Emergency Med, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA USA
[6] Emory Univ, Div Crit Care Med, Sch Med, Atlanta, GA USA
[7] Norton Womens & Childrens Hosp, Dept Pharm, 4001 Dutchmans Ln, Louisville, KY 40207 USA
[8] Emory Univ Hosp Midtown, Dept Pharm, 550 Peachtree St NE, Atlanta, GA 30308 USA
关键词
acute kidney injury; vancomycin; piperacillin-tazobactam; chronic kidney disease; nephrotoxicity; INJURY;
D O I
10.1177/08850666241234577
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The combination of vancomycin and piperacillin-tazobactam (VPT) has been associated with acute kidney injury (AKI) in hospitalized patients when compared to similar combinations. Additional studies examining this nephrotoxic risk in critically ill patients have not consistently demonstrated the aforementioned association. Furthermore, patients with baseline renal dysfunction have been excluded from almost all of these studies, creating a need to examine the risk in this patient population. Methods: This was a retrospective cohort analysis of critically ill adults with baseline chronic kidney disease (CKD) who received vancomycin plus an anti-pseudomonal beta-lactam at Emory University Hospital. The primary outcome was incidence of AKI. Secondary outcomes included stage of AKI, time to development of AKI, time to return to baseline renal function, new requirement for renal replacement therapy, intensive care unit and hospital length of stay, and in-hospital mortality. Results: A total of 109 patients were included. There was no difference observed in the primary outcome between the VPT (50%) and comparator (58%) group (P = .4), stage 2 or 3 AKI (15.9% vs 6%; P = .98), time to AKI development (1.7 vs 2 days; P = .5), time to return to baseline renal function (4 vs 3 days; P = .2), new requirement for RRT (4.5% vs 1.5%; P = .3), ICU length of stay (7.3 vs 7.4 days; P = .9), hospital length of stay (19.3 vs 20.1 days; P = .87), or in-hospital mortality (15.9% vs 10.8%; P = .4). A significant difference was observed in the duration of antibiotic exposure (3.32 vs 2.62 days; P = .045 days). Conclusion: VPT was not associated with an increased risk of AKI or adverse renal outcomes. Our findings suggest that the use of this antibiotic combination should not be avoided in this patient population. More robust prospective studies are warranted to confirm these findings.
引用
收藏
页码:860 / 865
页数:6
相关论文
共 50 条
  • [21] Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin
    Rutter, W. Cliff
    Burgess, David S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (07)
  • [22] Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin/tazobactam
    Holsen, Maya
    Meaney, Calvin
    Hassinger, Amanda
    Fusco, Nicholas
    PHARMACOTHERAPY, 2017, 37 (12): : E196 - E197
  • [23] Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem
    Robertson, Amy D.
    Li, Chenghui
    Hammond, Drayton A.
    Dickey, Tiffany A.
    PHARMACOTHERAPY, 2018, 38 (12): : 1184 - 1193
  • [24] Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study
    Hammond, Drayton A.
    Smith, Melanie N.
    Painter, Jacob T.
    Meena, Nikhil K.
    Lusardi, Katherine
    PHARMACOTHERAPY, 2016, 36 (05): : 463 - 471
  • [25] We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
    Menino Osbert Cotta
    Jason A. Roberts
    Jeffrey Lipman
    Critical Care, 20
  • [26] Vancomycin and Piperacillin-tazobactam Use in Obstetric Patients is Associated with Renal Injury
    Butler, Sharlay
    Su, Selma
    Megli, Christina
    Sarah, Bennett
    Trilling, Ariel
    Schmitz, Jourdan
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 226 (02) : 308 - 308
  • [27] Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients
    Kumta, Nilesh
    Heffernan, Aaron J.
    Cotta, Menino Osbert
    Liu, Xin
    Parker, Suzanne
    Wallis, Steven
    Livermore, Amelia
    Starr, Therese
    Wong, Wai Tat
    Joynt, Gavin M.
    Lipman, Jeffrey
    Roberts, Jason A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (02)
  • [28] Acute Kidney Injury during Vancomycin Therapy Associated with Combination Use of Piperacillin-Tazobactam after Allogeneic Stem Cell Transplantation
    Kariya, Misato
    Shimomura, Yoshimitsu
    Hiramoto, Nobuhiro
    Okada, Yutaka
    Ootoshi, Ai
    Maki, Haruka
    Hashimoto, Hisako
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S281 - S282
  • [29] The Effect of Vancomycin and Piperacillin-Tazobactam on Incidence of Acute Kidney Injury in Patients With Obesity
    Wuerger, Angela
    Bowden, Jarred
    Mitchell, Anna
    Marler, Jacob
    HOSPITAL PHARMACY, 2023, 58 (06) : 605 - 613
  • [30] Comparison of Acute Kidney Injury During Treatment with Vancomycin in Combination with Piperacillin-Tazobactam or Cefepime
    Gomes, Diane M.
    Smotherman, Carmen
    Birch, Amy
    Dupree, Lori
    Della Vecchia, Bethany J.
    Kraemer, Dale F.
    Jankowski, Christopher A.
    PHARMACOTHERAPY, 2014, 34 (07): : 662 - 669